Cargando…

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

BACKGROUND: The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calabrese, Joseph R., Jin, Na, Johnson, Brian, Such, Pedro, Baker, Ross A., Madera, Jessica, Hertel, Peter, Ottinger, Jocelyn, Amatniek, Joan, Kawasaki, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162003/ https://www.ncbi.nlm.nih.gov/pubmed/29886522 http://dx.doi.org/10.1186/s40345-018-0122-z

Ejemplares similares

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
por: Madera, Jessica, et al.
Publicado: (2019)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera, Jessica J, et al.
Publicado: (2019)

Aripiprazole in the acute and maintenance phase of bipolar I disorder
por: Zupancic, Melanie, et al.
Publicado: (2012)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza, Vanessa, et al.
Publicado: (2018)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland, Timothy, et al.
Publicado: (2019)

Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter 1‐year retrospective mirror image study
por: Goto, Junichi, et al.
Publicado: (2023)

Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
por: McIntyre, Roger S, et al.
Publicado: (2011)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
por: Tsai, Alexander C., et al.
Publicado: (2011)

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores
por: Ismail, Zahinoor, et al.
Publicado: (2017)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
por: Potkin, Steven G., et al.
Publicado: (2016)

Case report: rTMS in combination with aripiprazole and sodium valproate for the maintenance treatment of rapid cycling bipolar disorder
por: Tao, Siyi, et al.
Publicado: (2023)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study
por: Potkin, Steven G., et al.
Publicado: (2017)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
por: Clayton, Anita H, et al.
Publicado: (2014)

Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance
por: Sugimoto, Yuna, et al.
Publicado: (2021)

Treatment persistence with aripiprazole once monthly: a 4-year follow-up
por: Fagiolini, Andrea, et al.
Publicado: (2022)

When to start aripiprazole therapy in patients with bipolar mania
por: Sayyaparaju, Kiran Kumar, et al.
Publicado: (2014)

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
por: Kirino, Eiji
Publicado: (2014)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
por: Higuchi, Teruhiko, et al.
Publicado: (2021)

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
por: Yoshizawa, Yuta, et al.
Publicado: (2021)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
por: Fagiolini, Andrea
Publicado: (2010)

Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2010)

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
por: Muzina, David J
Publicado: (2009)

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review
por: Muneer, Ather
Publicado: (2016)

Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania
por: Rezayat, Amir Akhavan, et al.
Publicado: (2014)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_td6qcaka9h51d56oevodd42obs